Bayforest Capital Ltd Invests $257,000 in ICU Medical, Inc. $ICUI

Bayforest Capital Ltd acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, HoldingsChannel reports. The fund acquired 1,942 shares of the medical instruments supplier’s stock, valued at approximately $257,000.

Several other large investors also recently modified their holdings of the stock. Ameriprise Financial Inc. grew its position in ICU Medical by 18.5% in the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock valued at $96,326,000 after purchasing an additional 108,493 shares during the period. Invesco Ltd. grew its position in ICU Medical by 80.1% in the 1st quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier’s stock valued at $28,303,000 after purchasing an additional 90,674 shares during the period. Woodline Partners LP grew its position in ICU Medical by 31.6% in the 1st quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier’s stock valued at $22,344,000 after purchasing an additional 38,671 shares during the period. Victory Capital Management Inc. grew its position in ICU Medical by 5.7% in the 1st quarter. Victory Capital Management Inc. now owns 149,246 shares of the medical instruments supplier’s stock valued at $20,724,000 after purchasing an additional 8,101 shares during the period. Finally, Principal Financial Group Inc. grew its position in ICU Medical by 3.0% in the 1st quarter. Principal Financial Group Inc. now owns 136,009 shares of the medical instruments supplier’s stock valued at $18,886,000 after purchasing an additional 3,910 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Trading Up 0.2%

NASDAQ ICUI opened at $116.49 on Friday. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of -76.64 and a beta of 0.83. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $196.26. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The business’s fifty day moving average is $123.34 and its 200-day moving average is $130.20.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million for the quarter, compared to analysts’ expectations of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

ICUI has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Piper Sandler lifted their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. Finally, Raymond James Financial cut their price objective on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Insiders Place Their Bets

In other news, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the purchase, the chief executive officer owned 130,149 shares of the company’s stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Greenberg acquired 1,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the purchase, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. This trade represents a 17.75% increase in their position. The disclosure for this purchase can be found here. Insiders own 1.50% of the company’s stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.